Substituted Imidazole Derivatives for Selective α2 Agonist Sedation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for an α2 adrenoceptor agonist with good circulation stability, high potency, short duration, fast onset of action, and weak side effects to address sedative, analgesic, anesthetic, anti-anxiety, and sympathetic nerve inhibitory effects, as well as treatments for insomnia and mental disorders.

Innovation Solution

A substituted imidazole derivative with α2 adrenoceptor agonist activity, or its pharmaceutically acceptable salt, stereoisomer, or tautomer, is developed, which can be used in pharmaceutical compositions for producing sedative, analgesic, anesthetic, anti-anxiety effects, and inhibiting sympathetic nerve activity, and treating insomnia and mental disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If dexmedetomidine is used to produce sedative and analgesic effects, then high potency and good circulation stability are achieved, but hypotension and bradycardia occur as adverse reactions

Engineering Contradiction:

Improvecirculation stabilityVSAvoidhypotension and bradycardia

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces different substituent groups (R1, R2, R3) at specific positions of the imidazole ring to create local structural variations that selectively enhance α2 receptor binding while reducing activation of α1B receptors responsible for vasoconstriction and reflex bradycardia

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent systematically varies molecular parameters including the hydroxyl group position (n=1-3), substituent types (halogen, alkyl, alkoxy, etc.), and ring structure (cycloalkyl, heterocyclyl, heteroaryl) to optimize the balance between potency, circulation stability, and side effect profile

Inventive Principle:

Principle #35Parameter changes

2Reliability

If large doses of dexmedetomidine are administered to enhance analgesic and sedative effects, then high potency is achieved, but vasoconstriction and reflex heart rate decrease occur

Engineering Contradiction:

Improveanalgesic and sedative effectsVSAvoidvasoconstriction and reflex heart rate decrease

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent segments the pharmacological effects by designing molecules that preferentially bind to and activate α2A and α2C receptors (responsible for desired sedative and analgesic effects) while minimizing interaction with α1B receptors (responsible for harmful vasoconstriction and reflex bradycardia)

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses specific molecular structures as intermediaries that facilitate selective receptor binding - the substituted imidazole derivative acts as a mediator that transmits the desired pharmacological effect while filtering out the harmful vasoconstrictive pathway

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP4729516A1Substituted imidazole derivative, intermediate, preparation method therefor and use thereof

Publication Date: 2026.04.22 NHWA PHARMA CORPORATION

AI summary

The present invention relates to the field of medicines, and particularly relates to a compound represented by general formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer and a composition containing the compound, an intermediate thereof, a preparation method therefor and a use thereof in the field of medicines.